1. Product advantages
High purity, all above 98.5%, no impurities after dissolution
We will test each batch to ensure quality
OEM and private brand services designed for free
Various cap colors available
We can also provide MT1 peptide powder
2. Factory advantages
Professional research team
More than 5 doctors in high-tech R&D laboratories
More than 1000 m2 of factory production line to ensure stable supply
More than 1200 factories to manufacture products and control quality
3. Service advantages
24-hour online service
Track package information and update it for customers
Professional sales team
Accept small order service
Redelivery service if detained by customs

Product Introduction:

Ibrutinib is a Bruton tyrosine kinase (BTK) inhibitor for the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL). Both MCL and CLL belong to B-cell non-Hodgkin lymphoma, which is difficult to cure and easy to relapse, and the commonly used chemical immunotherapy is not targeted, and often occurs grade 3 or 4 adverse reactions. Ibrutinib can bind to BTK targeting, which is necessary for the formation, differentiation, information transmission and survival of B lymphocytes, irreversibly inhibit the activity of BTK, and effectively inhibit the proliferation and survival of tumor cells. After oral absorption is rapid, the maximum blood concentration can be reached in 1 to 2 hours, and the adverse reactions belong to grade 1 or 2, which will become a new choice for the treatment of CLL and MCL. On November 13, 2013, the U.S. food and drug administration (FDA) to accelerate the approved PharmaChemicalbookcyclics Johnson & Johnson company and the United States Imbruvica (common name: Ibrutinib (Ibrutinib) is marketed for the treatment of mantle cell lymphoma (MCL), a rare and aggressive blood cancer. Ibrutinib, a first-of-its-kind oral Bruton tyrosine kinase (BTK) inhibitor, was granted breakthrough therapy drug status by the FDA in February 2013 and approved as a treatment for MCL and CLL on November 13, 2013 and February 12, 2014, respectively. The drug irreversibly inhibits Btk by selectively covalently binding to the target BTK active site of cystine residue (Cys-481), thereby effectively preventing tumor migration from B cells to lymphoid tissue adapted to the tumor growth environment.

The B-cell antigen receptor (BCR) signaling pathway is a key driver of the growth and spread of many tumors. As an indispensable participant of BCR signaling peptide, BTK is essential for the formation, differentiation, information transmission and survival of B lymphocytes. BTK is a signal peptide molecule recognized by the BCR channel. When the signal peptide molecule passes through the receptor on the surface of B lymphocytes, the necessary channels for B lymphocytes to achieve transport, chemotaxis and adhesion are activated, which facilitates the formation of B-cell malignant tumors. Ibrutinib is a small molecule BTK inhibitor in Chemicalbook. It can selectively covalently bind to cysteine residue (Cys-481) at the active site of BTK, irreversibly inhibit the activity of BTK, and then inhibit the activation of BCR signaling pathway, effectively preventing tumor migration from B cells to lymphoid tissue suitable for tumor growth. Reduce the malignant proliferation of B cells and induce cell apoptosis, thus play a role in the treatment of CLL and MCL. Non-clinical studies have shown that ibrutinib can inhibit the proliferation and survival of malignant B lymphocytes in vivo.

Hebei Sankai Chemical Technology Co., Ltd. is a new chemical enterprise integrating the research, manufacturing and supply of chemicals. Located in the beautiful "cattle city" Xingtai, Hebei Sankai Chemical Technology Co., Ltd. is mainly engaged in the research of chemical fertilizer. At the same time, we have made great breakthroughs in food, feed additives, cosmetics, dyes and industrial chemicals. Our company spirit of "integrity management, quality control, customer first" belief, at home and abroad enjoy high reputation.